Standard BioTools Inc. (LAB) community

LABNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 12/3085% below fair value

$0.71+0.06 (+8.60%)

Close on Nov 13, 2026Market cap $277.71MP/E 3.2Yield –

Community

Notes and questions about Standard BioTools from other investors

No posts about LAB yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in Standard BioTools's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is LAB.

Compare: LAB vs BCYC · LAB vs TNGX · LAB vs WVE · LAB vs KPTIQ · LAB vs XLO

Revenue growth-4.8% · median 39.9%

Operating margin-112.8% · median -132.2%

Net margin100.4% · median -161.5%

Company	Revenue	Growth
KPTIQ	$146.62M	+6.8%
LAB	$84.60M	-4.8%
BCYC	$83.53M	+194.7%
WVE	$70.92M	–
XLO	$55.01M	+73.0%
TNGX	$0	-100.0%

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 389
Held by institutions: 75.4%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 1162194

Advertisement
300 × 250

See a number that looks wrong?